Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Tirzepatide is a novel dual agonist medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
by Richard Weil, M.Ed., CDE Founder and Director Transformation Weight Control I like to show the following slide when discussing side effects of GLP-1 receptor agonists
But thats the extent of data we have for the 104 week arm, everything else is 80 week data, so lets look at differences in weight loss in male vs female patients
The practical implication: if you are choosing between semaglutide and tirzepatide based solely on published trial outcomes (15% vs 20% weight loss), you are optimizing the wrong variable
US$ 25.05
US$ 20.30
US$ 22.21
US$ 29.04
